Home » News » Drug Sponsors » AOP Orphan spins off 80% stake in Activartis, outlines business strategy

AOP Orphan spins off 80% stake in Activartis, outlines business strategy

Wednesday, June 19, 2013

AOP Orphan Pharmaceuticals will spin off its 80% stake in Activartis, a Vienna-based biotech with a platform for immune-based cancer vaccines, to a group of private investors.

The dendritic cell-based technology for individualized tumor therapy developed by Activartis represents a unique therapeutic approach. Clinical development is at an advanced stage for glioblastoma, an incurable disease, and data from a multi-centric, prospective trial are expected soon.

“This spinoff has to be seen in the context of our development and commercialization strategy at AOP Orphan and is a consequence of Elan’s offer to acquire AOP Orphan,” said Rudolf Widmann, chief executive officer of AOP Orphan. “The goal of the Elan scenario would have been to pursue a course of rapid territorial expansion and the addition of several new orphan projects. However, AOP was a minor part of Elan’s management strategy, which included four business proposals, the main one being a royalty-based deal. This strategy was turned down by Elan’s shareholders.”

“AOP Orphan is in a financial position to pursue its research programs as a stand-alone company, and the divestment of Activartis allows it to go for a separate global commercial business case for the cancer vaccine program,” he said. “AOP Orphan will continue its research projects as planned in a timely manner and will launch at least two products within three years in the areas of hematology and cardiology.”

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!